main content start
How do you like the content?
Myelodysplastic Syndromes 6m 52s

Lenalidomide in MDS

Published 04 Oct 2022
Early phase clinical trials conducted 10 years ago laid foundation for use of Lenalidomide in low-risk transfusion dependent MDS patients. Lenalidomide showed promising efficacy in patients with Del 5q abnormality which is found in 2-5% of MDS patients. 65% of patients achieved RBC transfusion independence lasting for median 2 years duration. These results were subsequently confirmed in placebo-controlled phase 3 trial leading to approval of Lenalidomide in low risk MDS. Lenalidomide is associated with side effects like diarrhea while neutropenia and thrombocytopenia are observed more frequently in patients with Del 5q abnormality. P-53 & ROS mutations can impact efficacy of Lenalidomide, and blood or bone marrow based NGS is recommended to monitor evolution of disease.
del 5q abnormality lenalidomide low risk mds p-53 mutation

Disclaimer: The Views/Opinions expressed and/or opinions provided in Videos and other content on MedEnrich Website are those of respective speakers. They do not purport to reflect the opinion or views of Dr.Reddy’s Laboratories Limited or its affiliates (collectively Dr.Reddy’s)in any manner whatsoever and accordingly ,Dr.Reddys does not recommend , endorse or make any representation about the veracity and appropriateness of the views ,opinions/ information on MedEnrich website. Content on MedEnrich website may discuss uses and dosage for therapeutic product that may not have been approved in by the relevant regulatory agencies in your country. Dr.Reddy’s does not support , endorse or encourage any off-label use. Please refer to approved label before prescribing.

Perks of registering with us
Access to Online/Offline Events
Personalized Content
Access to all Features
Hi, can I help?
Chat SupportX
Support Team
Hello, how can I help you today?
Please select one of the below options.

Find Information

Unable to Login or Register

Want to share feedback